Alto Neuroscience Inc. (ANRO)
| Bid | 2.51 |
| Market Cap | 68.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.43M |
| EPS (ttm) | -2.48 |
| PE Ratio (ttm) | -1.02 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Ask | 2.54 |
| Volume | 87,255 |
| Avg. Volume (20D) | 321,970 |
| Open | 2.51 |
| Previous Close | 2.45 |
| Day's Range | 2.33 - 2.54 |
| 52-Week Range | 1.60 - 17.55 |
| Beta | 2.16 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphod...
Analyst Forecast
According to 6 analyst ratings, the average rating for ANRO stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 295.26% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Alto Neuroscience to Participate in Upcoming Investor ConferencesMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...
